Delaware-developed CRISPR cancer therapy edging closer to human testing

Christiana Care Health System ’s Gene Editing Institute is preparing a preliminary investigational new drug (IND) application that, if approved by the Food and Drug Administration, would allow the institute to begin human testing of a CRISPR therapy it is developing to treat non-small cell lung cancer. CRISPR, an acronym for Clustered Regularly Interspaced Short Palindromic Repeats, is a technique that allows researchers to alter DNA sequences and modify gene function. Christiana Care’s Gene…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Conclusion: miR-548e-5p directly binds to the 3′-UTR of UBE2C and decreases UBE2C mRNA expression. UBE2C is an oncogene that promotes EMT in lung cancer cells by directly targeting the 5′-UTR of the transcript encoding the E-cadherin repressor ZEB1/2. miR-548e-5p, UBE2C, and ZEB1/2 constitute the miR-548e-5p-UBE2C-ZEB1/2 signal axis, which enhances cancer cell invasiveness by directly interacting with e EMT marker proteins. We believe that the miR-548e-5p-UBE2C-ZEB1/2 signal axis may be a suitable diagnostic marker and a potential target for lung cancer therapy.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int. 2019;2019:9056417 Authors: Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY Abstract Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a larg...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Systemic anti-cancer therapy (SACT) is widely used in the treatment of lung cancer for both curative-intent settings where treatment is given to reduce the risk of recurrence, and in palliative-intent settings where treatment is given to prolong survival and mitigate symptoms [1,2]. While SACT is a powerful tool for managing lung cancer, it is not without serious side-effects. In order for SACT to be effective, patients must be able to withstand not only the immediate side-effects but to survive long enough for the benefits of SACT to be realized.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract PURPOSE: Prediction of spatially variant response to cancer therapies can inform risk-adaptive management within precision oncology. We developed the "Voxel Forecast" multiscale regression framework for predicting spatially variant tumor response to chemoradiotherapy on FDG-PET/CT imaging. EXPERIMENTAL DESIGN: Twenty-five patients with locally advanced non-small cell lung cancer, enrolled on the FLARE-RT phase II trial (NCT02773238), underwent FDG-PET/CT imaging prior to (PETpre) and during week 3 (PETmid) of concurrent chemoradiotherapy. Voxel Forecast was designed to predict tumor voxel S...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Emily Roarty Jing Wang Fei Yang Michelle Barton Jeffrey Rosen Sendurai Mani Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Unfortunately, a significant portion of cancers (including lung and breast cancers) do not respond to immunotherapy, and many of them develop resistance to chemotherapy. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusions: To develop small molecule-based PD-L1 PET imaging probes, we designed and synthesized a library of fluorinated PD-L1 ligands based on the biphenyl pharmacophore. In vitro binding assay showed that several of the compounds possess nano-molar affinities to human PD-L1, and are potential PD-L1 PET imaging probe candidates. The radiolabeling and in vitro and in vivo pharmacology and pharmacokinetics studies of these PET tracers are under the way. Figure 1. The structure of the lead compound and the regions for SAR
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Novel Radiochemistry for Cancer Applications Source Type: research
Conclusions: New IGF-1R targeted probe,68Ga-NOTA-ZIGF-1R:4:40, was synthesized successfully. And it could distinguish different IGF-1R expression levels, which was expected to guide IGF-1R targeted therapy and evaluate treatment efficacy in real time noninvasively.A large number of verification experiments were still needed to be studied. REFERENCE: [1] Coppola D, Ferber A, Miura M, et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 1994;14(7):4588-4595. [2] Baserga R. The insulin-like growth factor-I re...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology Posters Source Type: research
Conclusions: In NSCLC before and after cancer therapy, fractal dimension decreased in the PMR group and tended to increase in PMD group. The change of fractal dimension (D) by Box counting method or Pixel counting method in FDG uptake will be supplemental useful parameter for diagnosing cancer therapeutic effect in NSCLC
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors (Diagnosis) Source Type: research
COPENHAGEN, Denmark, May 15, 2019 -- (Healthcare Sales &Marketing Network) -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win® technology, announced the i... Biopharmaceuticals, Oncology IO Biotech, NSCLC, Immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Cancers, Vol. 11, Pages 627: Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer Cancers doi: 10.3390/cancers11050627 Authors: Yanhua Fan Huaiwei Ding Donghwa Kim Duc-Hiep Bach Ji-Young Hong Yongnan Xu Sang Kook Lee Aberrant activation of hepatocyte growth factor (HGF)/c-Met signaling pathway caused by gene amplification or mutation plays an important role in tumorigenesis. Therefore, c-Met is considered as an attractive target for cancer therapy and c-Met inhibitors have been developed with great interests. However, cancers treated with c-Met inhibitor...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Genetics | Health Management | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer